Urology Times Newsletter

CLINICAL UPDATES

How has the FDA’s mesh guidance affected POP treatment?

"I prefer doing transvaginal prolapse surgery with native tissue and always have. So I was not affected when mesh was restricted," says one urologist.

Read more comments

Dr. Angela Smith discusses FDA approval of Jelmyto for low-grade UTUC

The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.

Watch the video

Video: Study will test targeted PCa therapies based on genomic alterations

Martin Gleave, MD, discusses the Genomic Umbrella Neoadjuvant Study trial, which uses a multi-arm, multistage adaptive design to test targeted therapies in patients with high-risk localized disease by matching neoadjuvant therapies to baseline genomic alterations.

Watch the video

Taking advantage of stones that respond to urine alkalinization

Tim Large, MD, discusses the role of urine alkalinization in treatment for a patient with a staghorn uric acid kidney stone that compromised almost the entire renal pelvis. He shares how alkalinization can reduce stone complexity, cost and morbidity.

Watch the case study video now.